Retinoblastoma Phase II Expanded Access Clinical Trial
Phase 2
Recruiting
- Conditions
- Retinoblastoma
- Interventions
- Drug: Chemoplaque also referred to as Episcleral Topotecan
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT06679634
- Locations
- 🇺🇸
NewYork Presbyterian Morgan Stanley Children's Hospital, New York, New York, United States
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT04156347
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Phase 1
Active, not recruiting
- Conditions
- Macular EdemaCentral Serous Retinopathy With Pit of Optic DiscCommotio RetinaeEpiretinal MembraneVitritisRadiation RetinopathyBranch Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT04120311
- Locations
- 🇺🇸
Stanford Medicine Ophthalmology, Palo Alto, California, United States
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Phase 1
Active, not recruiting
- Conditions
- Macula EdemaEpiretinal MembraneCentral Serous Retinopathy With Pit of Optic DiscBranch Retinal Vein OcclusionCommotio RetinaeRadiation RetinopathyVitritis
- Interventions
- Drug: Episcleral Celecoxib
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 3
- Registration Number
- NCT04120636
- Locations
- 🇺🇸
Stanford Medicine Ophthalmology, Palo Alto, California, United States
A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema
Phase 1
Active, not recruiting
- Conditions
- Refractory Diabetic Macular Edema
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04005430
- Locations
- 🇺🇸
Stanford Medicine Ophthalmology, Palo Alto, California, United States
© Copyright 2025. All Rights Reserved by MedPath